Find a Research Study

PRIMARY: To assess the anti-tumor efficacy of combined therapy as determined by measurement of objective response rate (ORR) SECONDARY: To assess the anti-tumor efficacy of combined therapy as determined by measurement of overall survival (OS), progression free survival (PFS), duration of response (DOR) and disease control rate (DCR) as a total cohort and HRD versus HR proficient. To evaluate the safety and tolerability of radiotherapy added to Olaparib.

- Histologically confirmed metastatic gastric or GEJ adenocarcinoma that is amenable to biopsy either at primary or metastatic site. - Patient must consent at initiation of study to serial tumor biopsies during study. Irradiated lesions will not be considered for biopsy. For baseline biopsy, available archived tumor tissue of a metastatic tumor collected up to 28 days prior to registration is acceptable. If, after patient consent, the tumor is deemed inaccessible, the biopsy is not in the subject’s best interest per investigator discretion, or the patient refuses biopsy during course of the study, patients will be allowed to remain on study. - Participant must have at least one radiographically-confirmed index lesion that will not undergo RT and is measurable based on RECIST v1.1. - Participants must have received at least one line of therapy including a fluoropyrimidine and platinum drug. For participants with HER2+ tumors, they must have received trastuzumab. Adjuvant therapy does not count toward first-line therapy unless patient recurs within 6 months of completion. - Patients are excluded if they have known active CNS metastases and/or carcinomatous meningitis that requires ongoing treatment or are found to be progressing. Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov